150 related articles for article (PubMed ID: 30924126)
1. Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol.
Brackman DJ; Yee SW; Enogieru OJ; Shaffer C; Ranatunga D; Denny JC; Wei WQ; Kamatani Y; Kubo M; Roden DM; Jorgenson E; Giacomini KM
Clin Pharmacol Ther; 2019 Sep; 106(3):623-631. PubMed ID: 30924126
[TBL] [Abstract][Full Text] [Related]
2. Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.
Vora B; Brackman DJ; Zou L; Garcia-Cremades M; Sirota M; Savic RM; Giacomini KM
Clin Transl Sci; 2021 Jul; 14(4):1431-1443. PubMed ID: 33931953
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2.
Nakamura M; Fujita K; Toyoda Y; Takada T; Hasegawa H; Ichida K
Drug Metab Pharmacokinet; 2018 Feb; 33(1):77-81. PubMed ID: 29342419
[TBL] [Abstract][Full Text] [Related]
4. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites.
Pilon MO; Leclair G; Oussaïd E; St-Jean I; Jutras M; Gaulin MJ; Mongrain I; Busseuil D; Rouleau JL; Tardif JC; Dubé MP; de Denus S
Clin Transl Sci; 2022 Aug; 15(8):2024-2034. PubMed ID: 35689378
[TBL] [Abstract][Full Text] [Related]
5. [ROLE OF SLC2A9 AND ABCG2 GENE POLYMORPHISMS IN ORIGIN OF HYPERURICEMIA AND GOUT].
Fadieieva A; Prystupa L; Pogorelova O; Kirichenko N; Dudchenko I
Georgian Med News; 2016 Mar; (252):79-83. PubMed ID: 27119840
[TBL] [Abstract][Full Text] [Related]
6. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Merriman TR; Wright DFB; Drake J; Dalbeth N
Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
[TBL] [Abstract][Full Text] [Related]
7. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Torres RJ; Puig JG
Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
[TBL] [Abstract][Full Text] [Related]
8. ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinol.
Stamp LK; Wallace M; Roberts RL; Frampton C; Miner JN; Merriman TR; Dalbeth N
Drug Metab Pharmacokinet; 2018 Dec; 33(6):241-242. PubMed ID: 30274827
[No Abstract] [Full Text] [Related]
9. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response.
Wen CC; Yee SW; Liang X; Hoffmann TJ; Kvale MN; Banda Y; Jorgenson E; Schaefer C; Risch N; Giacomini KM
Clin Pharmacol Ther; 2015 May; 97(5):518-25. PubMed ID: 25676789
[TBL] [Abstract][Full Text] [Related]
10. ABCG2 rs2231142 variant in hyperuricemia is modified by SLC2A9 and SLC22A12 polymorphisms and cardiovascular risk factors in an elderly community-dwelling population.
Liu J; Yang W; Li Y; Wei Z; Dan X
BMC Med Genet; 2020 Mar; 21(1):54. PubMed ID: 32183743
[TBL] [Abstract][Full Text] [Related]
11. Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis.
Wallace MC; Roberts RL; Nanavati P; Miner JN; Dalbeth N; Topless R; Merriman TR; Stamp LK
Rheumatology (Oxford); 2018 Apr; 57(4):656-660. PubMed ID: 29342288
[TBL] [Abstract][Full Text] [Related]
12. Reactive oxygen species derived from xanthine oxidase interrupt dimerization of breast cancer resistance protein, resulting in suppression of uric acid excretion to the intestinal lumen.
Ogura J; Kuwayama K; Sasaki S; Kaneko C; Koizumi T; Yabe K; Tsujimoto T; Takeno R; Takaya A; Kobayashi M; Yamaguchi H; Iseki K
Biochem Pharmacol; 2015 Sep; 97(1):89-98. PubMed ID: 26119820
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
Turnheim K; Krivanek P; Oberbauer R
Br J Clin Pharmacol; 1999 Oct; 48(4):501-9. PubMed ID: 10583019
[TBL] [Abstract][Full Text] [Related]
14. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout.
Roberts RL; Wallace MC; Phipps-Green AJ; Topless R; Drake JM; Tan P; Dalbeth N; Merriman TR; Stamp LK
Pharmacogenomics J; 2017 Mar; 17(2):201-203. PubMed ID: 26810134
[TBL] [Abstract][Full Text] [Related]
15. The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool.
Wright DFB; Dalbeth N; Phipps-Green AJ; Merriman TR; Barclay ML; Drake J; Tan P; Horne A; Stamp LK
Br J Clin Pharmacol; 2018 May; 84(5):937-943. PubMed ID: 29341237
[TBL] [Abstract][Full Text] [Related]
16. Absorption and metabolism of allopurinol and oxypurinol by rat jejunum in vitro: effects on uric acid transport.
Shaw MI; Parsons DS
Clin Sci (Lond); 1984 Mar; 66(3):257-67. PubMed ID: 6692658
[TBL] [Abstract][Full Text] [Related]
17. Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story?
Reyes AJ; Leary WP
Cardiovasc Drugs Ther; 2005 Oct; 19(5):311-3. PubMed ID: 16382292
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of urate production by allopurinol.
Spector T
Biochem Pharmacol; 1977 Mar; 26(5):355-8. PubMed ID: 849329
[No Abstract] [Full Text] [Related]
19. Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical.
Spector T
Biochem Pharmacol; 1988 Jan; 37(2):349-52. PubMed ID: 2829916
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]